Grove Biopharma Reports Preclinical Study in Nature Communications Demonstrating a Novel Approach to MYC and KRAS Degradation
Grove Biopharma reports a preclinical Nature Communications study demonstrating a PLP-based approach to degrade oncogenic MYC and KRAS.
Why it mattersNature Communications-reported PLP-mediated MYC/KRAS degradation suggests oncology R&D should prioritize degrader-platform partnerships immediately.
Entities Mentioned
Grove BiopharmaNature Communications